Pre-screening for sensitivity to investigational anti-cancer drugs in patients with cancer
- Conditions
- advanced cancer (all indications)
- Registration Number
- DRKS00015060
- Lead Sponsor
- Oncology Venture ApS
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting stopped after recruiting started
- Sex
- All
- Target Recruitment
- 13
i. Histological or cytological documented locally advanced or metastatic solid tumor relapsed on 1 or more different prior therapies
ii. Age = 18 years
iii. Written informed consent
iv. Life expectancy = 6 months
v. ECOG Performance status = 1
vi. FFPE tumor tissue available
i. Other primary malignancy within the last 5 years prior to enrolment, except for adequately treated squamous cell carcinoma of the skin, or adequately controlled limited basal cell skin cancer.
ii. Evidence of any other disease or psychological dysfunction giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug, may affect patients understanding of the information, compliance with study routines, or place the patient at high risk from treatment related complications.
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To identify cancer patients with different indications with high likelihood of being sensitive to investigational cancer drugs, based on DRP® pre-screening of archival formalin-fixed paraffin embedded (FFPE) cancer tumor tissue from the time of diagnosis and/or the most recent re-biopsy, if available.
- Secondary Outcome Measures
Name Time Method To utilize the DRP® to do retrospective analysis of whether the DRP® method can predict and<br>confirm the obtained sensitivity to the prior given drugs used in the treatment of cancer as well as prospective analyses guiding the Investigators on future treatments.